Marshall Wace
ITOS

Marshall Wace’s iTeos Therapeutics ITOS Stock Holding History

Marshall Wace’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-611,649
Closed -$6.1M – 3124
2025
Q2 		$6.1M Buy
611,649
+492,091
+412% +$3.96M 0.01% 1050
2025
Q1 		$714K Buy
+119,558
New +$878K ﹤0.01% 1921
2023
Q3 		– Sell
-35,429
Closed -$469K – 2440
2023
Q2 		$469K Sell
35,429
-19,580
-36% -$279K ﹤0.01% 2011
2023
Q1 		$749K Buy
+55,009
New +$986K ﹤0.01% 1939
2022
Q2 		– Sell
-155,373
Closed -$5M – 3643
2022
Q1 		$5M Sell
155,373
-61,449
-28% -$2.23M 0.01% 1362
2021
Q4 		$10.1M Buy
216,822
+160,265
+283% +$5.33M 0.02% 856
2021
Q3 		$1.53M Sell
56,557
-86,372
-60% -$2.26M 0.01% 1733
2021
Q2 		$3.67M Buy
+142,929
New +$3.41M 0.02% 1025

Other funds holding ITOS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Marshall Wace's ITOS Position: Q3 2025 in Review

Marshall Wace sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 611,649 shares — an estimated $6.1M sold.

Marshall Wace first reported a position in ITOS in Q2 2021 and held it in 8 quarters. The position peaked at $10.1M in Q4 2021. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.

  • Marshall Wace reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Marshall Wace sold 611,649 iTeos Therapeutics shares in Q3 2025, an estimated $6.1M.
  • Marshall Wace first reported a position in iTeos Therapeutics in Q2 2021 and held it in 8 quarters.
  • Marshall Wace's iTeos Therapeutics position peaked at $10.1M in Q4 2021.
  • 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.

Based on Marshall Wace's 13F filing for Q3 2025, filed 13 Nov 2025.